Collectively, our prior report and the current study establish imaging technologies to quantify key early steps in CXCL12-CXCR4 signaling and analyze targeting of therapeutic agents in pre-clinical models of ovarian cancer. This evidence concerns the gene CXCL12 and ovarian cancer.